We are the missing piece in the fight against neurodegeneration: the world’s first Positron Emission Tomography (PET) Tracer targeting the NMDA receptor

We believe in a world where PET scans for the early detection of neurodegeneration are regarded as a normal part of one’s regular health checkup routine.

Awa Diagne, CEO
PET images showing a negative (top) and positive (bottom) diagnosis of neurodegeneration

Neuroimaging with positron emission tomography (PET) is the most powerful tool for understanding pharmacology, neurochemistry, and pathology in the living human brain. This technology combines high-resolution scanners to measure radioactivity throughout the human body with specific, targeted radioactive molecules, which allow measurements of a myriad of biological processes in vivo

Hooker, Jacob M., and Richard E. Carson. “Human positron emission tomography neuroimaging.” Annual Review of Biomedical Engineering 21 (2019): 551-581.

Technology

1st to Market

We have developed the only PET tracer that targets the NMDA receptor

Strong Patent Position

Global patent filed in 2018: All inventors are co-founders

→ Proof of Concept in Monkeys

Animal studies successful. We are currently embarking on clinical trials in humans

World’s First

We have developed the world’s first Positron Emission Tomography (PET) Tracer targeting the NMDA receptor

News

Publications

We successfully synthesized and evaluated 18F-OF-NB1 in rhesus monkeys. (…) Its attractive pharmacokinetic profile render it a promising candidate for clinical translation

Ahmed, Hazem, et al. “Evaluation of (rac)-,(R)-and (S)-18F-OF-NB1 for imaging GluN2B subunit-containing N-methyl-D-aspartate receptors in non-human primates.” Journal of Nuclear Medicine (2022).

News

Team

Awa Diagne

Chief Executive Officer

Awa Diagne is a Computer Engineering graduate from Ecole Polytechnique de Montreal and Strategy from HEC-Paris. She has over 15 years of international experience in business process optimization and digital transformation in Life Sciences and Natural Resources industries. As Management Consultant, she has been supporting Fortune 500 companies such as Merck, Roche and Novartis. She is Senegalo-Canadian and has been living and working across the globe (Africa, America, Europe, Asia) for the last 20+ years. Through her expertise, she will be able to implement industry best practices in the operations of the business. In her free time, Awa practices meditations, volunteering and water sports.

Prof. Dr. Simon Ametamay

Chief Scientific Officer

Simon Mensah Ametamey is a senior scientist at the Institute for Pharmaceutical Sciences of ETH Zurich (Group Radiopharmaceutical Science) since April 2005. He earned his doctorate degree in Organic Chemistry from the University of Zurich under the guidance of with Prof. H.H. Heimgartner. Subsequently, he spent one year as a postdoctoral fellow with Prof. K. Bernhard at Hoffmann La Roche, Basel, Switzerland. In January 1995, Simon M. Ametamey became the group leader of the Radiotracer Synthesis research group at the Center for Radiopharmaceutical Science of ETH, PSI and USZ in Villigen. In 2001, he completed his habilitation in Radiopharmaceutical Chemistry at ETH Zurich, Switzerland. At present, Simon M. Ametamey is co-​head of the Animal Imaging Center-​PET. His research activities concentrate on the development of radiolabelled biomolecules for diagnostic application in brain diseases and tumor imaging. Currently, his research work concentrates on PET ligands for glutamatergic neurotransmission, gene therapy monitoring and folate receptors.

Daniel Tay

Director, IT & Analytics

Daniel Tay completed his Bsc in Physics at the National University of Singapore, his Msc in Physical Sciences at the University of Chicago and is currently completing a PhD in Physics under Prof Gabriel Aeppli in the group of Prof Joel Mesot at ETH Zurich. His main research interest is in the use of Nuclear Magnetic Resonance (NMR) and Muon Spin Resonance (muSR) as local probes to image exotic electronic phenomena such as weyl semimetals, superconductivity and charge density waves. Daniel brings to the team his interdisciplinary scientific expertise and his data-driven approach to company finances. Daniel played goalkeeper in high school football and his favorite team is Liverpool.

Dr. Hazem Farouk

Advisory Board

Dr. Farouk is a pharmacist by training and a clinical researcher by experience. With in-depth knowledge within drug development, he obtained his PhD in Neuropharmacology and Radiopharmaceutical Sciences from the Swiss Federal Institutes of Technology, ETH Zurich. Focusing on patient-centred outcomes, Dr. Farouk is currently unravelling and tracing neurodegenerative diseases by positron emission tomography imaging while expediting the clinical translation of novel radiopharmaceuticals at the joint Centre of Radiopharmaceutical Sciences of ETH Zurich, University Hospital Zurich and Paul Scherrer Institute

Dr. Ahmed Haider

Advisory Board

Dr. Ahmed Haider studied pharmacology and obtained his PhD degree in Neuroimaging at the Swiss Federal Institute of Technology (ETH) in 2018. For his work on the early diagnosis of neurodegenerative disorders, such as Alzheimer’s Disease, Dr. Haider was awarded with the prestigious ETH Silver Medal and the Robert Eder Fonds Prize and has obtained 200’000 CHF of acquired project funding. He has collaborated with several pharmaceutical companies including Novartis, Roche, GE Healthcare and Takeda, thereby establishing a broad network within the pharmaceutical industry. After gaining insights into clinical studies at University Hospital Zurich for the past two years, Dr. Haider is currently moving his office to Boston (US), where he will be working at the Harvard Medical School and the Massachusetts General Hospital.

Blog at WordPress.com.